Biotech Values

[jbog]

Regulardoc,

We know very little about BG-12 after one trial dealing with a placebo arm.

Biogen said the drug cut relapses 49% after two years, compared to placebo, with an annual relapse reduction rate of 53%. It also reduced the progression of disability by 38%. In comparison, Teva Pharmaceutical Industries last week said its oral multiple sclerosis drug reduced the annual relapse rate by 23% and disability progression fell 36%.

The side effect profile will be very important but so far I think the data is in the ballpark of Gelinya.

I'm sure the fear today is that the two next BG12 PhIII trials that are to be reported later this year use Copaxone as the control arm. There is no love between Biogen and Teva.